Key Points
- CEO insider sale: Recursion CEO Najat Khan sold 28,298 shares on March 9 at an average price of $3.35 for about $94,798, trimming her stake by 1.24% to 2,262,085 shares (worth roughly $7.58M).
- Company & stock snapshot: Recursion beat Q results (EPS -$0.21 vs. -$0.28 est., revenue $35.54M, +671.7% YoY) but remains deeply unprofitable with a large negative net margin; shares trade near $3.28, consensus rating is "Hold" with a $9.40 price target.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Najat Khan sold 28,298 shares of the business's stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the completion of the sale, the chief executive officer directly owned 2,262,085 shares of the company's stock, valued at $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Najat Khan also recently made the following trade(s):
- On Monday, December 22nd, Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23.
Recursion Pharmaceuticals Stock Performance
RXRX stock traded down $0.18 on Thursday, hitting $3.28. The company's stock had a trading volume of 3,830,159 shares, compared to its average volume of 19,857,180. The firm has a 50 day moving average of $4.06 and a two-hundred day moving average of $4.60. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.98 and a 1 year high of $7.18. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -2.21 and a beta of 0.97. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The company had revenue of $35.54 million for the quarter, compared to analyst estimates of $24.56 million. During the same period in the previous year, the business posted ($0.53) earnings per share. Recursion Pharmaceuticals's quarterly revenue was up 671.7% on a year-over-year basis. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of large investors have recently modified their holdings of the company. Brighton Jones LLC lifted its position in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after buying an additional 6,699 shares in the last quarter. Royal Bank of Canada increased its position in shares of Recursion Pharmaceuticals by 627.6% in the first quarter. Royal Bank of Canada now owns 269,013 shares of the company's stock worth $1,423,000 after acquiring an additional 232,038 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock valued at $953,000 after acquiring an additional 12,372 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in Recursion Pharmaceuticals during the 1st quarter worth $77,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
RXRX has been the topic of several recent research reports. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday, February 28th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Bank of America decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $9.40.
Get Our Latest Research Report on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
